BioSpace News Archive

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced it has entered into a lease agreement to build an approximately 22,000 square foot facility in Rockville, Maryland

General Healthcare Resources Brand Sees Strong Year-Over-Year Growth

Deep Lens, Inc. recognized for achievements in Best Application of AI

The US Department of Health and Human Services announced that a total of approximately $107 million would be granted to 1,273 health centers across the whole country to improve the quality, efficiency and the value of the health care provided by these centers.

icometrix recognized for achievements in leading the brain imaging AI space

OncLive®, the nation’s leading multimedia resource focused on providing oncology professionals with the most current and insightful information they need to offer the best patient care, is pleased to announce that 2019 Giants of Cancer Care® inductee Eric P. Winer, M.D., director, breast oncology center, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute in Boston, Massachusetts,

Oct. 2, 2019 13:17 UTC LONDON--( BUSINESS WIRE )-- GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI), for the treatment of asthma in adults. Trelegy Ellipta was approved in the US in September 2017

Rising Pharma Holdings Inc. (“Rising Pharmaceuticals”), today announced the U.S. launch & commercialization of six new generic products during the third quarter 2019.

Point-of-care testing is transforming healthcare: this type of testing helps patients get diagnosed and treated faster, and also makes it easier for patients in remote areas to have access to medical testing

Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat superbug infections and combat antibiotic resistance, today announced that it met its first milestone three months ahead of schedule for the milestone-based contract worth up to $45 million from the Biomedical and Advanced Research Authority (BARDA), a division of the U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR).